<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1171">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05145907</url>
  </required_header>
  <id_info>
    <org_study_id>TJ107001STM202</org_study_id>
    <nct_id>NCT05145907</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors</brief_title>
  <official_title>A Multicenter, Open-label, Exploratory Phase II Clinical Study to Evaluate the Safety and Tolerability and Preliminary Efficacy of TJ107 Combine With Pembrolizumab Injection in Patients With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I-Mab Biopharma Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I-Mab Biopharma Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Purpose and Design:A Multicenter, Open-label, Exploratory Phase II Clinical Study to&#xD;
      Evaluate the Safety and Tolerability and Preliminary Efficacy of TJ107 in Combination with&#xD;
      Pembrolizumab Injection in Patients with Locally Advanced or Metastatic Solid Tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, multicenter phase 2 study will enroll 28 to 39 subjects in each of the&#xD;
      following 4 cohorts Cohort 1 Triple-negative breast cancer Cohort 2 Head and neck squamous&#xD;
      cell carcinoma Cohort 3 Other tumor species (to be determined) Cohort 4 Other tumor species&#xD;
      (to be determined) The trial consists of two phases, the first is a safety run-in phase and&#xD;
      the second is a case extension phase.&#xD;
&#xD;
      In the safety run-in phase, 3 subjects will be treated with TJ107 (1200 µg/kg q12w) combined&#xD;
      with Pembrolizumab Injection (200 mg q3w) first. A safety assessment was conducted by a&#xD;
      safety assessment committee composed of the sponsor and the investigator on the first dose in&#xD;
      these 3 subjects to determine that the dose of TJ107 1200 µg/kg was safe and to determine&#xD;
      whether to continue the safety assessment in these 3 patients, either at this dose level, or&#xD;
      at a dose or dosing interval adjustment (e.g., the dose of TJ107 was adjusted to 960 ug/kg or&#xD;
      the dosing interval was adjusted).&#xD;
&#xD;
      In the case expansion phase, 28-39 subjects will be enrolled in each cohort, and TJ107 (1200&#xD;
      µg/kg q12w) combined with Pembrolizumab Injection (200 mg q3w) or TJ107 adjusted dose&#xD;
      combined with Pembrolizumab Injection (200 mg q3w) will be administered until intolerance or&#xD;
      disease progression and other endpoint events occur.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, single arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of Adverse events</measure>
    <time_frame>Through the study assessed up to 2 years</time_frame>
    <description>The rate of Adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The rate of Senior Adverse Events</measure>
    <time_frame>Through the study assessed up to 2 years</time_frame>
    <description>The rate of Senior Adverse Events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">133</enrollment>
  <condition>Triple-negative Breast Cancer</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>TJ107+Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TJ107 1200ug/Kg,Q12W + Pembrolizumab 200mg Q3W</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TJ107 +Pembrolizumab</intervention_name>
    <description>TJ107 injection:1200ug/Kg, Q12W, IM; Pembrolizumab: 200mg, Q3W, IV</description>
    <arm_group_label>TJ107+Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged over 18 years (inclusive);&#xD;
&#xD;
          -  ECOG score: 0 - 2 points&#xD;
&#xD;
          -  Patients with histologically or cytologically confirmed locally advanced or metastatic&#xD;
             solid tumors, including TNBC and HNSCC&#xD;
&#xD;
          -  No previous treatment with CPI&#xD;
&#xD;
          -  Agreement to provide a previously archived tumor tissue specimen or biopsy to collect&#xD;
             tumor lesion tissue&#xD;
&#xD;
          -  Subject has at least 1 measurable lesion as defined by RECIST V1.1&#xD;
&#xD;
          -  Expected survival ≥ 6 months&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Males of childbearing potential or females of childbearing potential must use highly&#xD;
             effective contraceptive methods during the trial and continuing for 6 months after the&#xD;
             last dose&#xD;
&#xD;
          -  The subject voluntarily joined the study and signed an informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Prior cell therapy;&#xD;
&#xD;
          -  Received systemic anti-tumor therapy within 2 weeks or 5 half-lives of the treatment&#xD;
             agent (whichever is shorter) before the start of treatment;&#xD;
&#xD;
          -  Previous or current presence of two or more primary tumors&#xD;
&#xD;
          -  Patients with active autoimmune diseases&#xD;
&#xD;
          -  Have received systemic treatment with corticosteroids (10 mg prednisone equivalent&#xD;
             daily) or other immunosuppressive agents for more than 7 days within 2 weeks before&#xD;
             the start of treatment&#xD;
&#xD;
          -  Received investigational drugs within 2 weeks before the start of treatment;&#xD;
&#xD;
          -  Major surgery or serious trauma within 4 weeks before the start of treatment;&#xD;
&#xD;
          -  Patients with symptomatic central nervous system (CNS) metastasis&#xD;
&#xD;
          -  Active viral infectious disease requiring systemic treatment at screening:&#xD;
&#xD;
          -  Known serious hypersensitivity history&#xD;
&#xD;
          -  Uncontrolled pleural effusion, ascites, or pericardial effusion at screening;&#xD;
&#xD;
          -  Presence or history of active interstitial lung disease;&#xD;
&#xD;
          -  Patients with hypertension that cannot be well controlled with medical therapy.&#xD;
&#xD;
          -  Presence of clinically significant cardiovascular disease&#xD;
&#xD;
          -  Deep venous thrombosis within 6 months before the start of treatment&#xD;
&#xD;
          -  Thrombolytic therapy within 10 days prior to the start of treatment&#xD;
&#xD;
          -  Any active infection requiring intravenous anti-infective therapy before the start of&#xD;
             treatment&#xD;
&#xD;
          -  Had toxicity not resolved to ≤ Grade 1 (CTCAE 5.0) from previous anticancer therapy&#xD;
&#xD;
          -  Known or suspected inability to comply with the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liyang Song, Master</last_name>
    <role>Study Director</role>
    <affiliation>I-Mab Biopharma Co. Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaolin Wang, Bachelor</last_name>
    <phone>+86 13825619560</phone>
    <email>xiaolin.wang@i-mabbiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wang</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yingying Du</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Binghe Xu, Doctor</last_name>
      <phone>+86 13501028690</phone>
      <email>bhxu@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangzhou</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jing Huang, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hainan General Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lin Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qingyuan Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Youhua Zhu</last_name>
    </contact>
    <investigator>
      <last_name>Youhua Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xinhong Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College of Huzhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Huihua Xiong</last_name>
    </contact>
    <investigator>
      <last_name>Huihua Xiong</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guangyuan Hu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xianling Liu</last_name>
    </contact>
    <investigator>
      <last_name>Xianling Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enxiang Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jilin Guowen Hospital</name>
      <address>
        <city>Chang chun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jingzi Huang</last_name>
    </contact>
    <investigator>
      <last_name>Jingzi Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qun Su</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ying Cheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wei Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yanbian University Hospital</name>
      <address>
        <city>Yanji</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Songnan Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Funan Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jian Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ye Guo, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital,Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Laiping Zhong, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Bin Jiang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laiping Zhong, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhongsheng Tong</last_name>
    </contact>
    <investigator>
      <last_name>Zhongsheng Tong</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xudong Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xian Wang</last_name>
    </contact>
    <investigator>
      <last_name>Xian Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaonan Sun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Meiyu Fang</last_name>
    </contact>
    <investigator>
      <last_name>Meiyu Fang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhanhong Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Triple-negative breast cancer</keyword>
  <keyword>Head and neck squamous cell carcinoma</keyword>
  <keyword>Solid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

